China Drug Delivery Devices Market Size and Share - Growth Analysis Report and Forecast Trends 2026-2030

The China Drug Delivery Devices Market covers the full spectrum of administration technologies used in hospitals, clinics, retail pharmacies, and home-care settings across the country. With a base value of about USD 36.75 billion in 2025 and a projected 15.59% annual growth rate, the market is on track to roughly double within five years. Demand is concentrated in therapeutic areas such as oncology, diabetes, cardiovascular disease, and autoimmune conditions, where advanced delivery formats improve compliance and clinical outcomes.

• •Market size in 2025 is approximately USD 36.75 billion, with a 15.59% CAGR through the forecast horizon
• •Rising prevalence of diabetes, cancer, and respiratory illness is expanding the patient base for advanced delivery formats
• •Domestic and multinational device makers are scaling production capacity to meet growing clinical and home-care demand

A combination of demographic and structural factors is propelling market expansion in China. The National Medical Products Administration (NMPA) has accelerated approval pathways for innovative drug-device combinations, encouraging global manufacturers to localize production. Rising disposable income and the central government's Healthy China 2030 initiative are also widening access to advanced therapies that depend on sophisticated delivery technology.

• •Aging population and growth in chronic disease are increasing long-term demand for self-administration devices
• •Regulatory reforms and faster NMPA reviews are encouraging launches of connected and combination products
• •Expansion of biologics, biosimilars, and GLP-1 therapies is driving demand for prefilled syringes, auto-injectors, and pen injectors

Injectable devices represent the largest product segment, led by prefilled syringes and auto-injectors, while inhalation devices and transdermal patches are growing rapidly alongside nebulizer-based therapies for respiratory disease. Implantable systems such as central venous catheters and infusion ports serve oncology and long-term IV care, often concentrated in tier-1 and tier-2 city hospitals. Regional demand is heaviest in eastern metropolitan clusters including Beijing, Shanghai, Guangzhou, and Shenzhen, with secondary momentum in Chengdu, Wuhan, and Hangzhou.

• •Injectables dominate revenue, with auto-injectors, pen injectors, and prefilled syringes representing the fastest-growing sub-segments
• •Oncology and diabetes care are the leading therapeutic applications, followed by respiratory and cardiovascular disease
• •Eastern coastal provinces drive most volume, while inland tier-2 cities are emerging as the next growth frontier

What are the recent trends and outlook?

The most pronounced trend is the rise of connected and smart drug delivery devices, including Bluetooth-enabled auto-injectors and patch pumps paired with companion apps for adherence monitoring. Local manufacturing of auto-injectors and prefilled syringes is scaling rapidly as Chinese producers capture share previously held by imports. Looking ahead, the market is expected to maintain double-digit growth through 2030, supported by biologics adoption, hospital modernization, and the steady expansion of home-based self-injection.

• •Connected drug delivery devices are the fastest-growing sub-segment, supported by telehealth and adherence-monitoring demand
• •Domestic production capacity for prefilled syringes and auto-injectors is expanding quickly under government industrial policies
• •Sustained 15%+ annual growth is expected as biologics penetration and home-care self-administration continue to scale